Delicious

Expert: Research Shows Selenium To Be Effective Treatment Against Breast Cancer

Research on attaching selenium to the leading clinical chemotherapeutic monoclonal antibody for a type of breast cancer shows it can more effectively kill the cancer cells.

Read more...

Cancer drug destroys tumours in pre-clinical trials

Scientists at QIMR Berghofer Medical Research Institute have used an experimental drug produced from the seeds of a rainforest plant to cure solid cancer tumours in pre-clinical trials.
 
The study led by Dr Glen Boyle at QIMR Berghofer’s Cancer Drug Mechanisms group found a single injection of the drug EBC-46 led to rapid breakdown of tumours in a range of human tumour models.

Read more...

Curcumin, Special Peptides Boost Cancer-Blocking PIAS3 to Neutralize Cancer-Activating STAT3 in Mesothelioma

A common Asian spice and cancer-hampering molecules show promise in slowing the progression of mesothelioma, a cancer of the lung’s lining often linked to asbestos. Scientists from Case Western Reserve University and the Georg-Speyer-Haus in Frankfurt, Germany, demonstrate that application of curcumin, a derivative of the spice turmeric, and cancer-inhibiting peptides increase levels of a protein inhibitor known to combat the progression of this cancer. Their findings appeared in the Aug. 14 online edition Clinical Cancer Research; the print version of the article will appear Oct. 1.

Read more...

‘Electronic skin’ could improve early breast cancer detection

For detecting cancer, manual breast exams seem low-tech compared to other methods such as MRI. But scientists are now developing an “electronic skin” that “feels” and images small lumps that fingers can miss. Knowing the size and shape of a lump could allow for earlier identification of breast cancer, which could save lives. They describe their device, which they’ve tested on a breast model made of silicone, in the journal ACS Applied Materials & Interfaces.

Read more...

FDA approves first non-invasive DNA screening test for colorectal cancer

The U.S. Food and Drug Administration today approved Cologuard, the first stool-based colorectal screening test that detects the presence of red blood cells and DNA mutations that may indicate the presence of certain kinds of abnormal growths that may be cancers such as colon cancer or precursors to cancer.

Read more...

Page 1 of 45

Go to top